Skip to main
ORKA
ORKA logo

ORKA Stock Forecast & Price Target

ORKA Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oruka Therapeutics Inc is well-positioned for growth due to the promising performance of its lead programs, ORKA-001 and ORKA-002, which target key inflammatory pathways associated with psoriasis and other indications. The company has demonstrated an increased probability of approval for ORKA-001 from 40% to 45%, reflecting confidence in its potential as a best-in-class treatment option, particularly if its pharmacokinetic advantages translate to enhanced clinical outcomes. Additionally, the expected acceleration in the growth of Bimzelx through 2025 serves as a positive indicator for the market potential of ORKA-002, reinforcing the overall favorable outlook for the company's innovative therapeutic offerings.

Bears say

Oruka Therapeutics Inc faces significant risks that contribute to a negative outlook, including the potential inability to advance its lead product candidates ORKA-001 and ORKA-002 into pivotal trials and demonstrate compelling efficacy in ongoing psoriasis and psoriatic arthritis trials. The possibility of delays in completing regulatory filings, failure to secure necessary approvals, and intense competition in the immunology therapeutic landscape further exacerbate these challenges. Additionally, the observed lower efficacy of its product icotrokinra compared to established injectable treatments raises concerns about market demand and long-term dilution risks for investors.

ORKA has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oruka Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oruka Therapeutics Inc (ORKA) Forecast

Analysts have given ORKA a Strong Buy based on their latest research and market trends.

According to 8 analysts, ORKA has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oruka Therapeutics Inc (ORKA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.